323 related articles for article (PubMed ID: 25027606)
41. Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany.
Gandjour A; Ostwald DA
Appl Health Econ Health Policy; 2020 Feb; 18(1):109-125. PubMed ID: 31701482
[TBL] [Abstract][Full Text] [Related]
42. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents.
Gan EY; Chong WS; Tey HL
BioDrugs; 2013 Aug; 27(4):359-73. PubMed ID: 23580094
[TBL] [Abstract][Full Text] [Related]
43. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.
Gossec L; Coates LC; de Wit M; Kavanaugh A; Ramiro S; Mease PJ; Ritchlin CT; van der Heijde D; Smolen JS
Nat Rev Rheumatol; 2016 Dec; 12(12):743-750. PubMed ID: 27829672
[TBL] [Abstract][Full Text] [Related]
44. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
Chastek B; White J; Van Voorhis D; Tang D; Stolshek BS
Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
[TBL] [Abstract][Full Text] [Related]
45. [Not Available].
Perrotta FM; Lubrano E
Reumatismo; 2016 Sep; 68(2):57-64. PubMed ID: 27608793
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases.
Picchianti-Diamanti A; Spinelli FR; Rosado MM; Conti F; Laganà B
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807944
[TBL] [Abstract][Full Text] [Related]
47. Targeted therapies for psoriatic arthritis: an update for the dermatologist.
Elman SA; Weinblatt M; Merola JF
Semin Cutan Med Surg; 2018 Sep; 37(3):173-181. PubMed ID: 30215635
[TBL] [Abstract][Full Text] [Related]
48. Oral treatment options for AS and PsA: DMARDs and small-molecule inhibitors.
Chan J; Gladman D
Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):415-426. PubMed ID: 31171312
[TBL] [Abstract][Full Text] [Related]
49. Psoriatic Arthritis: Newer and Older Therapies.
Chao R; Kavanaugh A
Curr Rheumatol Rep; 2019 Dec; 21(12):75. PubMed ID: 31865449
[TBL] [Abstract][Full Text] [Related]
50. An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis.
Betts KA; Griffith J; Friedman A; Zhou ZY; Signorovitch JE; Ganguli A
Curr Med Res Opin; 2016; 32(4):721-9. PubMed ID: 26743448
[TBL] [Abstract][Full Text] [Related]
51. Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis.
Mavropoulos A; Zafiriou E; Simopoulou T; Brotis AG; Liaskos C; Roussaki-Schulze A; Katsiari CG; Bogdanos DP; Sakkas LI
Rheumatology (Oxford); 2019 Dec; 58(12):2240-2250. PubMed ID: 31209492
[TBL] [Abstract][Full Text] [Related]
52. Apremilast: first global approval.
Poole RM; Ballantyne AD
Drugs; 2014 May; 74(7):825-37. PubMed ID: 24797159
[TBL] [Abstract][Full Text] [Related]
53. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease.
Young M; Roebuck HL
J Am Assoc Nurse Pract; 2016 Dec; 28(12):683-695. PubMed ID: 27869356
[TBL] [Abstract][Full Text] [Related]
54. Tofacitinib: A Review in Psoriatic Arthritis.
Paik J; Deeks ED
Drugs; 2019 Apr; 79(6):655-663. PubMed ID: 30895473
[TBL] [Abstract][Full Text] [Related]
55. ▼ Apremilast for psoriasis and psoriatic arthritis.
Drug Ther Bull; 2015 Sep; 53(9):105-8. PubMed ID: 26358317
[TBL] [Abstract][Full Text] [Related]
56. Spondyloarthropathies: Apremilast: welcome advance in treatment of psoriatic arthritis.
FitzGerald O
Nat Rev Rheumatol; 2014 Jul; 10(7):385-6. PubMed ID: 24846499
[No Abstract] [Full Text] [Related]
57. Treatment of psoriatic arthritis with traditional DMARD's and novel therapies: approaches and recommendations.
Maharaj AB; Chandran V
Expert Rev Clin Immunol; 2017 Apr; 13(4):319-331. PubMed ID: 27826996
[TBL] [Abstract][Full Text] [Related]
58. Tofacitinib in psoriatic arthritis.
Wang TS; Tsai TF
Immunotherapy; 2017 Nov; 9(14):1153-1163. PubMed ID: 28967798
[TBL] [Abstract][Full Text] [Related]
59. JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?
Kerrigan SA; McInnes IB
Curr Rheumatol Rep; 2018 Nov; 20(12):83. PubMed ID: 30406861
[TBL] [Abstract][Full Text] [Related]
60. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
